re: eif, just keeps getting better
4 September 2003 To: Announcements Section ASX Company: Australian Stock Exchange No. of Pages: 2 EIFFEL TECHNOLOGIES SIGNS LARGE DRUG DELIVERY COMPANY FOR INHALED INSULIN Eiffel Technologies Limited (ASX:EIF) is pleased to announce that it has recently signed an agreement with a large US-based drug delivery company to develop an inhalable form of insulin and to undertake pre-clinical research and development using product modified through Eiffel’s proprietary supercritical fluid (SCF) technology. The terms and conditions of this agreement preclude disclosure of the party and commercial details until the research work is completed, which is expected to take up to 12 months. Eiffel will be dispatching the first shipment of reengineered insulin in the next few weeks, and anticipates completing the insulin product reengineering aspects of the transaction over the next eight weeks. The value of the global market for the delivery of oral, transdermal, injectable and inhalable drugs is estimated to be between US$40-50 billion, and is growing 2 to 3 times faster than the overall pharmaceutical market. The global diabetes market is valued at US$6 billion annually. According to the World Health Organisation, approximately 177 million people worldwide suffer from diabetes, and that number may double by 2005. Nearly 40% of people with diabetes require insulin injections. “This new agreement supports Eiffel’s external insulin research program which is focussed on jointly developing other forms of insulin delivery” said Eiffel MD and CEO, Christine Cussen. “A particular emphasis of our external program is to develop forms of insulin relevant to inhalation and transdermal delivery, with potential licensees undertaking pre-clinical and clinical studies” she went on to say. In addition to its external program, Eiffel is also undertaking an in-house insulin reengineering program focussed on producing an improved injectable form of the drug, with Eiffel bearing the cost of early stage pre-clinical and clinical development prior to licensing its proprietary technology to pharmaceutical companies. In mid-2002, Eiffel successfully reengineered injectable insulin, and in pre-clinical studies demonstrated that its nano-sized drug particles are more effective than current pharmacy grade product. The Company expects to undertake further pre-clinical and clinical studies of its proprietary reengineered injectable insulin. Eiffel Technologies Limited’s business focus is on improving the performance and delivery of a broad range of pharmaceuticals. Based in Melbourne, Australia, the Company has effectively over 50 years experience in pharmaceutical particle reengineering and is at the forefront of SCF research. Eiffel is developing and commercialising a range of drug reengineering platforms to improve drug performance and delivery and extend patent life. Eiffel Technologies’ research programme focuses on developing and improving drugs in a range of therapeutic areas including diabetes, asthma, cardiovascular disease, and antiinflammatory and antiviral formulations. For more information on Eiffel Technologies, please visit the Company’s website www.eiffeltechnologies.com.au. For further information on Eiffel, please contact:- Ms Christine Cussen Tom Hartigan Managing Director & Chief Executive Officer Chairman Eiffel Technologies Limited Eiffel Technologies Limited Phone: +61 3 9629 8022 Phone: +61 2 9460 2114 Mobile: 0407 532 756 Mobile: 0416 293 886 Email: [email protected]
EIF Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held